PF-Atlas › Mechanisms › Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s
Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s in IPF
Mechanism of action · idiopathic pulmonary fibrosis
Overview
Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 0 clinical trials acting through this mechanism.
Drugs targeting Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s
Therapies
Medical disclaimer. This is a research summary, not medical advice.